柔胺 | 4305-54-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 柔胺
• 英文名称: Ristosamin
• 英文别名: Daunosamin；4-Amino-6-methyloxane-2,5-diol
• CAS: 4305-54-8；88929-50-4；88929-51-5
• 化学式: C₆H₁₃NO₃
• mdl: MFCD19206011
• 分子量: 147.174
• InChiKey: BBMKQGIZNKEDOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  75.7
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

文献信息

• PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY
  申请人：Transfert Plus, S.E.C.

  公开号：EP3925969A1

  公开（公告）日：2021-12-22

  The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer relating to compound of formula YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.

  本公开涉及用于治疗癌症的多肽化合物和共轭化合物、工艺、方法和用途，涉及式中的化合物 ykslrrkaprwdaplrdpalrqll (xi) (SEQ ID NO: 11) 其中至少一个保护基团和/或至少一种标记剂可选地在 N 端和/或 C 端与所述多肽化合物连接。
• Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
  申请人：Emory University

  公开号：US10286113B2

  公开（公告）日：2019-05-14

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

  本公开涉及用于骨形成、骨折治疗、骨移植、骨融合、软骨维护和修复的化合物和组合物及其相关方法。在某些实施方案中，本公开涉及包含一种或多种本文公开的化合物的组合物，例如克霉唑、霍诺酚、麦格诺尔、他克莫司、吡美莫司、西罗莫司、依维莫司、西罗莫司、依维莫司、替米考酚酯、螺内酯、氟替卡松、丙酸氟替卡松、糠酸氟替卡松、利奈唑胺、替米沙坦、氯霉素、视黄醇、异维A酸、阿曲汀、依曲替酸、维A酸、维甲酸、替尼泊苷、丝裂霉素 C、阿糖胞苷、地西他滨、长春新碱、长春瑞滨、长春瑞滨、长春瑞滨、瓦鲁比星、多柔比星、达诺比星、表柔比星、依达比星、伊达比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、多柔比星、依达比星、依达比星、米托蒽醌、匹蒽醌、普利霉素、帕唑帕尼、拓扑替康、喜树碱、伊立替康、舒尼替尼、衍生物或其盐，用于骨生长过程。在一个典型的实施方案中，骨移植组合物被植入受试者所需骨生长或增强的部位。
• Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
  申请人：TRANSFERT PLUS, S.E.C.

  公开号：US11034727B2

  公开（公告）日：2021-06-15

  The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected from the following group consisting of; GVRAKAGVRNMFKSESY as set forth in SEQ ID NO: 9; GVRAKAGVRN(Nle)FKSESY as set forth in SEQ ID NO: 10; and YKSLRRKAPRWDAPLRDPALRQLL as set forth in SEQ ID NO: 11; and wherein at least one protecting group and/or at least one labelling agent is connected to said peptide compound.

  本公开涉及用于治疗癌症和增加所述多肽化合物的细胞内化的多肽化合物和共轭化合物、工艺、方法和用途。所述多肽化合物选自下组，包括：SEQ ID NO: 9 所列的 GVRAKAGVRNMFKSESY；SEQ ID NO: 10 所列的 GVRAKAGVRN(Nle)FKSESY；以及 SEQ ID NO: 11 所列的 YKSLRRKAPRWDAPLRDPALRQLL；其中至少一个保护基团和/或至少一种标记剂与所述多肽化合物相连。
• BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO
  申请人：Boden Scott D.

  公开号：US20140248372A1

  公开（公告）日：2014-09-04

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
• Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto
  申请人：Emory University

  公开号：US20160361470A1

  公开（公告）日：2016-12-15

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.